Most Read

RNDP-001 is an iPSC-derived dopamine neuron progenitor intended to treat inherited as well as idiopathic forms of Parkinson’s disease. The company will submit an investigational new drug (IND)

The partnership will combine the research capabilities of Dr Emyr Lloyd-Evans & Dr Helen Waller-Evans in lysosomal biology, MDI’s drug discovery capabilities and the fragment-based drug discovery platform

Jemperli has been designed to attach to the PD-1 receptor and blocks its interaction with the PD-L1 and PD-L2 ligands. The antibody received accelerated approval in April 2021

The two firms expect the agency to recommend marketing authorization approval for the monoclonal antibody AVT04, as soon as in the second half of this year. Stelara is

Adtralza has received approval to treat AD in people aged 12 to 17 years whose disease is not adequately controlled with topical prescription therapies or when those therapies

Danon Disease is a fatal genetic cardiac disease for which there are no disease-altering treatments currently available. RMAT designation was granted by the regulatory body based on positive

After granting priority review for the application, the FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of 5 August 2023. The drug is being evaluated

TAKHZYRO is a completely human monoclonal antibody that particularly binds and reduces plasma kallikrein activity.   Before this approval, the only approved routine prophylaxis treatment options for children

These therapies activate the immune response selectively within the microenvironment of the tumours. Purple Biotech is acquiring all the shares of Immunorizon in exchange for $3.5m upfront payment